Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.35 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.33 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.33 |
| ▸ | NT5E | P21589 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18324635 | 1.00 | FGFR1 (0.35) | FGFR1SLC22A6PDE4DPDE3ASLC29A1 | |
| SCHEMBL22765438 | 1.00 | FGFR1 (0.35) | FGFR1SLC22A6PDE4DPDE3ASLC29A1 | |
| SCHEMBL19245259 | 0.89 | FGFR1 (0.34) | FGFR1SLC22A6PDE4DPDE3ASLC29A1 | |
| SCHEMBL18324638 | 0.88 | FGFR1 (0.36) | FGFR1SLC22A6PDE4DPDE3ASLC29A1 | |
| SCHEMBL19049978 | 0.81 | FGFR1 (0.39) | FGFR1SLC22A6PDE4DPDE3ASLC29A1 | |
| SCHEMBL23950133 | 0.80 | FGFR1 (0.37) | FGFR1SLC22A6PDE4DPDE3ASLC29A1 | |
| SCHEMBL22847460 | 0.80 | FGFR1 (0.37) | FGFR1SLC22A6PDE4DPDE3ASLC29A1 | |
| SCHEMBL22351846 | 0.80 | — | — | |
| SCHEMBL19050051 | 0.79 | FGFR1 (0.38) | FGFR1SLC22A6PDE4DPDE3ASLC29A1 | |
| SCHEMBL16426709 | 0.78 | FGFR1 (0.43) | FGFR1SLC22A6PDE4DPDE3ASLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11707477-B2 | Formulation comprising a gemcitabine-prodrug | NuCana plc (GB) | 2023-07-25 | — | — | US | disclosed |
| US-20220031727-A1 | FORMULATION COMPRISING A GEMCITABINE-PRODRUG | NUCANA BIOMED LIMITED (GB) | 2022-02-03 | — | — | US | disclosed |
| US-10786523-B2 | Formulation comprising a gemcitabine-prodrug | NuCana plc (GB) | 2020-09-29 | — | — | US | disclosed |
| US-20190022118-A1 | FORMULATION COMPRISING A GEMCITABINE-PRODRUG | NuCana plc (GB) | 2019-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190022118-A1 | FORMULATION COMPRISING A GEMCITABINE-PRODRUG | TYMP, PNP, DPYD | FGFR1 2197/4885SLC22A6 768/4885PDE4D 512/4885 |
| US-10786523-B2 | Formulation comprising a gemcitabine-prodrug | TYMP, PNP, DPYD | FGFR1 2197/4885SLC22A6 768/4885PDE4D 512/4885 |
| US-20220031727-A1 | FORMULATION COMPRISING A GEMCITABINE-PRODRUG | PNP, TYMP, DPYD | FGFR1 2338/4885SLC22A6 947/4885PDE4D 460/4885 |
| US-11707477-B2 | Formulation comprising a gemcitabine-prodrug | PNP, TYMP, DPYD | FGFR1 2338/4885SLC22A6 947/4885PDE4D 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.